The presence of CD20+ cells and CD8+ cells and their co-localization was shown to improve antitumor response and was correlated with increased survival in ovarian cancer, breast cancer, and malignant melanoma (47–49). This evidence concerns the gene CD8A and ovarian carcinoma.